The new €275 million facility will be used to manufacture drugs for cancer and cardiovascular disease and is expected to be operational in 2024.
German Chancellor Olaf Scholz at the groundbreaking ceremony for Bayer’s new pharmaceutical production plant in Leverkusen [Credit: Bayer AG].
Bayer AG celebrated the completion of its new pharmaceutical facility in Leverkusen, Germany.
German Federal Chancellor Olaf Scholz, German Minister of Health, Prof. Dr. Karl Lauterbach and other guests from politics and business attended the ceremony.
The new Solida-1 production plant will be one of the most modern pharmaceutical production plants in the world. It is part of a billion euro investment program that Bayer is implementing to strengthen its pharmaceutical production network and the company’s internal innovation capacity.
“The construction of the new Solida-1 production plant will help us ensure that the results of scientific research are transformed into products as quickly as possible, thus improving the lives of patients in the long term”, commented Werner Baumann, Chairman of the Board. Board of Directors of Bayer SA. “The facility will be used to manufacture drugs for the treatment of cancer and cardiovascular disease, for example.”
The plant will be at the heart of the new global center of excellence for the production of solid pharmaceuticals at the Leverkusen site. According to the company, not only will it set standards for efficiency, quality, security of supply and sustainability, but it will also reap the benefits of digitalization in a “learning factory” – an environment in which flows of data are analyzed using artificial intelligence in order to derive recommendations for action.
“The investment in the new production plant demonstrates great confidence in the region as a center for the chemical and pharmaceutical industry”, commented Olaf Scholz during his visit to Leverkusen.
The construction of the new €275 million plant is both part of Bayer’s pharmaceutical strategy and an element of the company’s sustainability program. Its energy needs are largely met by a state-of-the-art geothermal power plant that reduces CO2 70% emissions compared to conventional systems.
Looking to the future, the modular construction of Solida-1 facilitates expansions of the installation, to react to future developments in the pharmaceutical industry.
The single-storey facility with a total area of approximately 15,000 m2 should be ready for operation in 2024.